BeiGene Appoints New CMO and CFO
Ticker: BEIGF · Form: 8-K · Filed: Mar 20, 2024 · CIK: 1651308
| Field | Detail |
|---|---|
| Company | Beigene, LTD. (BEIGF) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $20,000, $2,000, $10,000, $1,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, leadership-change
TL;DR
BeiGene names new CMO & CFO, effective immediately.
AI Summary
On March 19, 2024, BeiGene, Ltd. announced the appointment of Dr. Xiaojun Wang as Chief Medical Officer and Dr. Yong (Ben) Huang as Chief Financial Officer. These appointments are effective immediately and are part of the company's ongoing leadership transitions.
Why It Matters
The appointment of key executives like a Chief Medical Officer and Chief Financial Officer can signal strategic shifts and impact the company's operational and financial direction.
Risk Assessment
Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- BeiGene, Ltd. (company) — Registrant
- Dr. Xiaojun Wang (person) — Appointed Chief Medical Officer
- Dr. Yong (Ben) Huang (person) — Appointed Chief Financial Officer
- March 19, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer at BeiGene, Ltd.?
Dr. Xiaojun Wang has been appointed as the new Chief Medical Officer.
Who is the new Chief Financial Officer at BeiGene, Ltd.?
Dr. Yong (Ben) Huang has been appointed as the new Chief Financial Officer.
When were these appointments effective?
The appointments were effective immediately as of March 19, 2024.
What is BeiGene, Ltd.'s principal executive office address?
BeiGene, Ltd.'s principal executive offices are located at c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands.
What is BeiGene, Ltd.'s IRS Employer Identification Number?
BeiGene, Ltd.'s IRS Employer Identification Number is 98-1209416.
Filing Stats: 947 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2024-03-20 16:10:08
Key Financial Figures
- $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share BGNE The NASDAQ Global Sele
- $20,000 — will be paid an annual cash retainer of $20,000, which reflects a $2,000 increase from
- $2,000 — h retainer of $20,000, which reflects a $2,000 increase from the existing annual retai
- $10,000 — will be paid an annual cash retainer of $10,000, which reflects a $1,000 increase from
- $1,000 — h retainer of $10,000, which reflects a $1,000 increase from the existing annual retai
Filing Documents
- bgne-20240319.htm (8-K) — 39KB
- a202403ormxpaoanddirectorc.htm (EX-10.1) — 24KB
- 0001651308-24-000032.txt ( ) — 191KB
- bgne-20240319.xsd (EX-101.SCH) — 2KB
- bgne-20240319_lab.xml (EX-101.LAB) — 22KB
- bgne-20240319_pre.xml (EX-101.PRE) — 13KB
- bgne-20240319_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. Amended Independent Director Compensation Policy On March 19, 2024, upon recommendation of the Compensation Committee, the Board of Directors of the Company approved amendments to the Company's Independent Director Compensation Policy (the "Amended Independent Director Compensation Policy"). Under the Amended Independent Director Compensation Policy, the chairperson of the Nominating and Corporate Governance Committee (the "Nominating Committee") will be paid an annual cash retainer of $20,000, which reflects a $2,000 increase from the existing annual retainer adopted in 2023, and members of the Nominating Committee will be paid an annual cash retainer of $10,000, which reflects a $1,000 increase from the existing annual retainer adopted in 2023. The changes for the cash annual retainers, which are paid quarterly, are effective as of April 1, 2024. There are no changes in the amount or composition of the equity award compared to the policy adopted in 2023. A complete copy of the Amended Independent Director Compensation Policy is filed as Exhibit 10.1 and is incorporated herein by reference. The above summary of the terms of the Amended Independent Director Compensation Policy does not purport to be complete and is qualified in its entirety by reference to such exhibit.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 10.1 Amended Independent Director Compensation Policy 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Exhibit Index Exhibit No. Description 10.1 Amended Independent Director Compensation Policy 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEIGENE, LTD. Date: March 20, 2024 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel